Exhibit 99.1 SOUTH SAN FRANCISCO, Calif., March 26, 2025 -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the fourth quarter and year ended December 31, 2024. Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights "As the validation of cellular therapy in autoimmune disease expands to include CAR NK cells, we remain confident that the potential safety ...

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimmune indications expected in second half of 2025Restructuring and workforce reduction of 34% (53 positions), including freezing of some future hires, to extend cash runway by more than one year to enable clinical milestones while having ample cash runway following the realization of those milestonesCash balance ...

Nkarta, Inc. (NKTX) has been beaten down lately with too much selling pressure. While the stock has lost 33.6% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.Guide to Identifying Oversold StocksWe use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that ...

Core Viewpoint - Nkarta, Inc. (NKTX) has experienced a significant downtrend, with a 32.6% decline in stock price over the past four weeks, but it is now in oversold territory, suggesting a potential turnaround due to improved earnings expectations from analysts [1]. Group 1: Technical Indicators - The Relative Strength Index (RSI) is a key technical indicator used to identify oversold stocks, with a reading below 30 typically indicating oversold conditions [2]. - NKTX has an RSI reading of 28, suggesting that the heavy selling pressure may be exhausting, indicating a potential bounce back towards equilibrium in supply and demand [5]. Group 2: Fundamental Analysis - There is strong consensus among sell-side analysts regarding NKTX's earnings, with a 0.7% increase in the consensus EPS estimate over the last 30 days, which often correlates with price appreciation [6]. - NKTX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate revisions and EPS surprises, further supporting the potential for a near-term turnaround [7].

Company Overview - Nkarta, Inc. is a clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies for autoimmune diseases [2] - The company utilizes a combination of cell expansion, cryopreservation platforms, proprietary cell engineering technologies, and CRISPR-based genome engineering to create its therapies [2] Upcoming Events - Nkarta will participate in the TD Cowen 45th Annual Health Care Conference on March 3, 2025, at 3:10 p.m. ET for a fireside chat [1] - The company will also be present at the Leerink Partners 2025 Global Healthcare Conference on March 10, 2025, at 3:00 p.m. ET for another fireside chat [1] - Both events will be available via simultaneous webcast on Nkarta's website, with replays archived for approximately 90 days [1]

Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts Investigator-Sponsored Trial (IST) expands the development of NKX019 to neuromuscular autoimmune disease myasthenia gravis Patient dosing initiated and enrollment open in Ntrust-1 and IST of NKX019 in systemic lupus erythematosus Clinical data from Ntrust-1 and Ntrust-2 planned for 2025 SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a b ...

Company Overview - Nkarta, Inc. is a clinical-stage biotechnology company focused on developing engineered natural killer (NK) cell therapies [2] - The company utilizes a combination of cell expansion, cryopreservation platforms, proprietary cell engineering technologies, and CRISPR-based genome engineering to advance its therapies [2] Upcoming Events - Nkarta will participate in the Stifel 2024 Healthcare Conference on November 19, 2024, at 10:55 a.m. ET, featuring a fireside chat [1] - A simultaneous webcast of the event will be available on Nkarta's website, with a replay archived for approximately 90 days [1]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39370 Nkarta, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 47-4515206 (State or other jurisdiction of ...

Financial Performance - Nkarta reported a cash balance of $405.3 million as of September 30, 2024, expected to fund operations into late 2027[6]. - Research and development (R&D) expenses for Q3 2024 were $25.3 million, with a net loss of $28.3 million or $0.39 per share[6][19]. - Total operating expenses for Q3 2024 were $33.8 million, compared to $29.3 million in Q3 2023[19]. - General and administrative (G&A) expenses for Q3 2024 were $8.5 million, with non-cash stock-based compensation of $2.3 million included[6][19]. - Nkarta's total assets increased to $532.0 million as of September 30, 2024, up from $378.9 million at the end of 2023[20]. Clinical Trials and Development - The first patient was dosed in both the Ntrust-1 trial for lupus nephritis and the investigator-sponsored trial for systemic lupus erythematosus[2][3]. - Enrollment in the Ntrust-2 trial is expected to begin by year-end 2024, targeting systemic sclerosis, myositis, and vasculitis[4]. - Nkarta will not pursue further development of NKX019 in non-Hodgkin lymphoma, focusing instead on autoimmune diseases[5][2]. - Preliminary clinical data from Ntrust-1 and Ntrust-2 trials is planned for release in 2025[4]. - The company aims to report final data from the LBCL cohort at a future medical conference[5].

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference: H.C. Wainwright 26th Annual Global Investment Conference September 10, 2024 12:30 p.m. ET – fireside chat A simultaneous webcast of each event will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the ...